Head-To-Head Comparison: Abivax (NASDAQ:ABVX) and Celularity (NASDAQ:CELU)

Abivax (NASDAQ:ABVX) and Celularity (NASDAQ:CELU) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, profitability, analyst recommendations, risk and valuation.

Insider & Institutional Ownership

47.9% of Abivax shares are owned by institutional investors. Comparatively, 19.0% of Celularity shares are owned by institutional investors. 17.3% of Celularity shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Abivax and Celularity, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1	2	12	0	2.73
Celularity	1	0	1	0	2.00

Abivax presently has a consensus price target of $130.08, indicating a potential upside of 34.72%. Celularity has a consensus price target of $6.00, indicating a potential upside of 741.63%. Given Celularity’s higher possible upside, analysts plainly believe Celularity is more favorable than Abivax.

Valuation and Earnings

This table compares Abivax and Celularity”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27 million	($5.21)	-18.53
Celularity	$26.55 million	0.78	-$91.72 million	($3.33)	-0.21

Celularity has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Abivax has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, Celularity has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500.

Profitability

This table compares Abivax and Celularity’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Celularity	-345.45%	N/A	-77.94%

Summary

Celularity beats Abivax on 7 of the 13 factors compared between the two stocks.

About Abivax

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

About Celularity

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.